Chaemin K. Yoon

State Key Laboratory Of Emerging Infectious Diseases, Hong Kong Special Administrative Region
Lika, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A Malaysian study on COVID-19 (SARS-CoV-2) vaccination immune response in haemodialysis patients: A prospective, multicentre, cohort study.

A Malaysian study on COVID-19 (SARS-CoV-2) vaccination immune response in haemodialysis patients: A prospective, multicentre, cohort study.

Journal: The Medical journal of Malaysia

Published: January 30, 2026

Author Correction: An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.

Author Correction: An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.

Journal: Nature communications

Published: December 15, 2025

YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.

YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.

Journal: Nature communications

Published: September 01, 2025

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.

Journal: Research square

Published: November 28, 2024

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.

Journal: Nature communications

Published: November 14, 2024

Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3.

Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3.

Journal: Nature communications

Published: April 12, 2024

Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination.

Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination.

Journal: Cell discovery

Published: August 28, 2023

Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathways.

Type-II IFN inhibits SARS-CoV-2 replication in human lung epithelial cells and ex vivo human lung tissues through indoleamine 2,3-dioxygenase-mediated pathways.

Journal: Journal of medical virology

Published: August 08, 2023

Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract.

Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract.

Journal: EBioMedicine

Published: July 31, 2023

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.

Journal: EBioMedicine

Published: April 19, 2023

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants.

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants.

Journal: Signal transduction and targeted therapy

Published: February 04, 2023

Altered host protease determinants for SARS-CoV-2 Omicron.

Altered host protease determinants for SARS-CoV-2 Omicron.

Journal: Science advances

Published: January 20, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026